LY500307 is a potent, selective estrogen receptor β agonist with an EC50 of 0.66 nM. LY500307 is selective (32-fold) toward ERβ and shows full agonist function in both ERα and ERβ assays (90% relative efficacy). [1] LY500307 is a drug used to treat prostate diseases. A phase 2 clinical study was carried out to evaluate daily oral doses of LY500307 for 24 weeks in men with lower urinary tract symptoms (LUTS) and prostatic enlargement secondary to benign prostatic hyperplasia (BPH). [2]
The pharmacological and toxicological properties of this product have not been fully investigated. Exercise caution in use and handling. This product must not be used in humans.